Wizbiotech COVID19 Antigen Test listed in EU Common List
According to the latest HSC Common List published on October 17, 2022, the SARS-CoV-2 Antigen Rapid Test produced by Wizbiotech has been listed in EU Common List Categories A.
The EU common list of COVID-19 antigen tests has been split up in two categories:
Category A: Antigen tests for which their performance has been evaluated through prospective clinical field studies and that meet the criteria agreed on 21 September 2021 (see section 2.2) have been placed under the “A-category” of the EU common list. Category A.1 sets out the eligible COVID-19 rapid antigen tests and Category A.2 sets out the eligible COVID-19 laboratory-based antigenic assays.
Category B: Antigen tests for which their performance has been evaluated through retrospective in vitro studies and that meet the criteria agreed on 21 September 2021 (see section 2.2) have been placed under the “B-category” of the EU common list. Category B.1 sets out the eligible COVID-19 rapid antigen tests and Category B.2 sets out the eligible COVID-19 laboratory-based antigenic assays.
Since the outbreak of the epidemic, Wizbioteh has continued to pay attention to the epidemic situation and committed to the prevention and control of the global epidemic. So far, Wizbiotech's COVID-19 solution including COVID-19 antigen/antibody/influenza differential detection products. COVID-19 series products have obtained certifications of EU, UK, Malaysia and other countries.
Wizbiotech will continue to focus on diagnostic techniques to improve the quality of life!
